Growth Metrics

NovoCure (NVCR) Depreciation & Amortization (CF) (2016 - 2026)

NovoCure's Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $4.1 million for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 24.03% to $4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.4 million, a 31.54% increase, with the full-year FY2025 number at $14.6 million, up 30.4% from a year prior.
  • Depreciation & Amortization (CF) hit $4.1 million in Q1 2026 for NovoCure, down from $4.2 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for NVCR hit a ceiling of $4.2 million in Q4 2025 and a floor of $2.5 million in Q3 2024.
  • Historically, Depreciation & Amortization (CF) has averaged $3.0 million across 5 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): dropped 12.31% in 2024 and later surged 49.02% in 2025.
  • Tracing NVCR's Depreciation & Amortization (CF) over 5 years: stood at $2.7 million in 2022, then increased by 0.85% to $2.7 million in 2023, then rose by 13.99% to $3.1 million in 2024, then surged by 35.89% to $4.2 million in 2025, then fell by 2.23% to $4.1 million in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for NVCR at $4.1 million in Q1 2026, $4.2 million in Q4 2025, and $3.7 million in Q3 2025.